Medtech & Diagnostics Analyst Osborn, along with Paul Schalch Lepe, MD, FACS, Clinical Assistant Professor, University of California, discuss Nyxoah’s upcoming DREAM data and use case in the U.S. on an Analyst/Industry conference call to be held on February 7 at 11 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NYXH:
- Nyxoah price target raised to $15 from $10 at Piper Sandler
- Nyxoah Stock (NASDAQ:NYXH): Don’t You Dare Sleep on This Little Runner
- Nyxoah Announces 2024 Strategic Priorities
- Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023
- Nyxoah sees Q4 revenue EUR 1.8M up 40% YoY, sees FY23 revenue EUR 4.3M
